Allarity Therapeutics Inc. (ALLR) Total Debt to Capital

Allarity Therapeutics (ALLR) protects its market position through a unique DRP therapy selection system that creates high barriers to entry for competitors under FDA supervision. However, geopolitical instability and sanctions are slowing the logistics of biomaterials and the execution of global tests. This chart of GURU.Markets exchange quotes shows a debt-to-equity ratio of 5.94, while Allarity Therapeutics (ALLR) adheres to standard environmental waste disposal regulations.

This ratio allows an investor to compare the volume of external liabilities with net assets, determining the business's degree of dependence on borrowed capital and its financial stability. For Allarity Therapeutics (ALLR), which utilizes the DRP AI platform to accelerate clinical trials, low leverage is critical for scaling patents, a fact clearly reflected in the debt-to-equity ratio dynamics.